Monday, November 11, 2013

Shire acquires ViroPharma for $4.20 billion

Shire has hit the acquisition trail and is spending $4.20 billion to buy the US rare disease specialist ViroPharma.

The Ireland-headquartered group is paying $50 per share, which represents a 27% premium on ViroPharma's closing share price on November 8. The deal gives Shire access to the hereditary angioedema drug Cinryze (C1 inhibitor [human]), which complements its own HAE drug Firazyr (icatibant).

No comments: